Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=18300585&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Treatment of refractory and/or severe ANCA-associated systemic necrotizing vasculitides Guillevin L; Pagnoux CIsr Med Assoc J 2008[Jan]; 10 (1): 89-91Treatment of vasculitides has progressed markedly over the past few decades. Recent therapeutic strategies in severe and refractory anti-neutrophil cytoplasmic antibodies-associated vasculitides include immunomodulating methods (e.g., plasma exchanges), products (such as intravenous immunoglobulins) and, more recently, new agents called biotherapies. Some of them (e.g., anti-tumor necrosis factor-alpha and anti-CD20 monoclonal antibodies) have achieved promising results and are now often used to treat severe cases.|Anti-Inflammatory Agents/therapeutic use[MESH]|Antibodies, Antineutrophil Cytoplasmic/blood[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Antigens, CD20/immunology[MESH]|Humans[MESH]|Immunoglobulins, Intravenous/therapeutic use[MESH]|Immunologic Factors/therapeutic use[MESH]|Immunosuppressive Agents/therapeutic use[MESH]|Infliximab[MESH]|Necrosis/immunology/therapy[MESH]|Plasma Exchange[MESH]|Tumor Necrosis Factor-alpha/antagonists & inhibitors[MESH]|Vasculitis/immunology/*therapy[MESH] |
